Optimising evidence-based treatments for patients with chronic kidney disease (CKD)
The Oberoi Disease Management Digital Audit Platform for CKD is aligned with the latest evidence for the treatment of CKD (NICE guidelines NG203 (2021) and NG28 (2022).
The Oberoi Disease Management CKD module also utilises the Kidney Disease: Improving Global Outcomes (KDIGO) classification to support the recall and review of patients.
To access grant funding for primary care to optimise evidence-based treatments for patients with CKD through the use of the Oberoi Disease Management Digital Audit Platform for CKD, contact email@example.com or call 01332 224 251 to set up an introductory call.
Kidney disease: A UK public health emergency
We commissioned an independent report into the economic impact of kidney disease in the UK.
- Kidney disease is costing the UK economy £7 billion a year, costs which could rise to £13.9 billion in just ten years
- Growing numbers of people are at risk of kidney disease due to increased cases of diabetes, heart disease, high blood pressure and obesity
- Significant government action is needed to implement four healthcare interventions that could save 10,000 lives in the UK by 2033